136 related articles for article (PubMed ID: 30860495)
1. Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy.
Badarni M; Prasad M; Balaban N; Zorea J; Yegodayev KM; Joshua BZ; Dinur AB; Grénman R; Rotblat B; Cohen L; Elkabets M
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30860495
[TBL] [Abstract][Full Text] [Related]
2. HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
Meister KS; Godse NR; Khan NI; Hedberg ML; Kemp C; Kulkarni S; Alvarado D; LaVallee T; Kim S; Grandis JR; Duvvuri U
Sci Rep; 2019 Jun; 9(1):9130. PubMed ID: 31235758
[TBL] [Abstract][Full Text] [Related]
3. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.
Iida M; McDaniel NK; Kostecki KL; Welke NB; Kranjac CA; Liu P; Longhurst C; Bruce JY; Hong S; Salgia R; Wheeler DL
BMC Cancer; 2022 Apr; 22(1):447. PubMed ID: 35461210
[TBL] [Abstract][Full Text] [Related]
4. AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia.
Vandewalle N; Satilmis H; Verheye E; Fan R; Wang Y; De Groof TWM; Bridoux J; Kerre T; De Beule N; De Becker A; De Bruyne E; Menu E; Vanderkerken K; Breckpot K; Devoogdt N; De Veirman K
Theranostics; 2024; 14(7):2656-2674. PubMed ID: 38773967
[No Abstract] [Full Text] [Related]
5. Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
Danielli SG; Wurth J; Morice S; Kisele S; Surdez D; Delattre O; Bode PK; Wachtel M; Schäfer BW
Mol Cancer Ther; 2024 Jun; 23(6):864-876. PubMed ID: 38471796
[TBL] [Abstract][Full Text] [Related]
6. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts.
Mills KA; Quinn JM; Roach ST; Palisoul M; Nguyen M; Noia H; Guo L; Fazal J; Mutch DG; Wickline SA; Pan H; Fuh KC
Sci Rep; 2019 Mar; 9(1):4762. PubMed ID: 30886159
[TBL] [Abstract][Full Text] [Related]
7. AXL receptor as an emerging molecular target in colorectal cancer.
De Rosa L; Di Stasi R; Fusco V; D'Andrea LD
Drug Discov Today; 2024 Jun; 29(6):104005. PubMed ID: 38685399
[TBL] [Abstract][Full Text] [Related]
8. Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression.
Arnold L; Gomez JP; Barry M; Yap M; Jackson L; Ly T; Standing D; Padhye SB; Biersack B; Anant S; Thomas SM
Explor Target Antitumor Ther; 2023; 4(5):1104-1121. PubMed ID: 38023989
[TBL] [Abstract][Full Text] [Related]
9. ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation.
Chen M; Yin B; Liu Y; Li M; Shen S; Wu J; Li W; Fan J
Cell Cycle; 2024 Jan; 23(1):56-69. PubMed ID: 38389126
[TBL] [Abstract][Full Text] [Related]
10. AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer.
Marquez-Palencia M; Reza Herrera L; Parida PK; Ghosh S; Kim K; Das NM; Gonzalez-Ericsson PI; Sanders ME; Mobley BC; Diegeler S; Aguilera TA; Peng Y; Lewis CM; Arteaga CL; Hanker AB; Whitehurst AW; Lorens JB; Brekken RA; Davis AJ; Malladi S
Cancer Res; 2024 Mar; 84(5):675-687. PubMed ID: 38190717
[TBL] [Abstract][Full Text] [Related]
11. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
[TBL] [Abstract][Full Text] [Related]
12. c-FOS drives reversible basal to squamous cell carcinoma transition.
Kuonen F; Li NY; Haensel D; Patel T; Gaddam S; Yerly L; Rieger K; Aasi S; Oro AE
Cell Rep; 2021 Oct; 37(1):109774. PubMed ID: 34610301
[TBL] [Abstract][Full Text] [Related]
13. Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer.
Yip HYK; Shin SY; Chee A; Ang CS; Rossello FJ; Wong LH; Nguyen LK; Papa A
NPJ Precis Oncol; 2024 Jan; 8(1):20. PubMed ID: 38273040
[TBL] [Abstract][Full Text] [Related]
14. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
15. CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3Kα Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma.
Remer E; Badarni M; Hikri E; Dayan A; Levi L; Popovtzer A; Iraqi M; Porgador A; Joshua BZ; Bachar G; Elkabets M; Scaltriti M; Mizrachi A
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33036331
[TBL] [Abstract][Full Text] [Related]
16. IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer.
Badarni M; Prasad M; Golden A; Bhattacharya B; Levin L; Yegodayev KM; Dimitstein O; Joshua BZ; Cohen L; Khrameeva E; Kong D; Porgador A; Braiman A; Grandis JR; Rotblat B; Elkabets M
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34067117
[TBL] [Abstract][Full Text] [Related]
17. CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.
Cheng M; Chen S; Li K; Wang G; Xiong G; Ling R; Zhang C; Zhang Z; Han H; Chen Z; Wang X; Liang Y; Tian G; Zhou R; Zhu Y; Ma J; Liu J; Lin S; Xu H; Chen D; Li Y; Peng L
Nat Commun; 2024 Apr; 15(1):2818. PubMed ID: 38561369
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the functionally elusive TAM receptor family.
Miao YR; Rankin EB; Giaccia AJ
Nat Rev Drug Discov; 2024 Mar; 23(3):201-217. PubMed ID: 38092952
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer stem cells tolerate chromosomal instability during tumor progression via c-Jun/AXL stress signaling.
Baba SA; Sun Q; Mugisha S; Labhsetwar S; Klemke R; Desgrosellier JS
Heliyon; 2023 Sep; 9(9):e20182. PubMed ID: 37809421
[TBL] [Abstract][Full Text] [Related]
20. Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.
Novoplansky O; Shnerb AB; Marripati D; Jagadeeshan S; Abu Shareb R; Conde-López C; Zorea J; Prasad M; Ben Lulu T; Yegodayev KM; Benafsha C; Li Y; Kong D; Kuo F; Morris LGT; Kurth I; Hess J; Elkabets M
Mol Oncol; 2023 Dec; 17(12):2618-2636. PubMed ID: 37501404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
